TXG

Equity

10x Genomics, Inc.

Health Care · Health Information Services

$23.05

+23.05 (+0.00%)

Open

N/A

Day Range

$21.21 - $23.10

52W Range

$6.78 - $23.56

Volume

3M

Price History

Key Statistics

Market Cap

N/A

P/E Ratio

N/A

EPS

N/A

Dividend Yield

N/A

P/B Ratio

N/A

Payout Ratio

N/A

ROE

N/A

Debt/Equity

N/A

Latest News

Is It Time To Reassess 10x Genomics (TXG) After Its 1 Year Share Price Surge

Simply Wall St. 12 hours ago

3 Stocks Under $50 We’re Skeptical Of

StockStory 2 days ago

UBS Adjusts Price Target on 10x Genomics to $20 From $14, Maintains Neutral Rating

MT Newswires Feb 20, 2026

10x Genomics to Participate in the 46th Annual TD Cowen Health Care Conference

PR Newswire Feb 19, 2026

5 Must-Read Analyst Questions From 10x Genomics’s Q4 Earnings Call

StockStory Feb 19, 2026

Peers in Health Care

Symbol Name Price Mkt Cap Div Yield Change
ACAD ACADIA Pharmaceuticals Inc. $24.56 N/A - +0.00%
ABT Abbott Laboratories $116.35 N/A 2.06% +0.00%
AKBA Akebia Therapeutics, Inc. $1.31 N/A - +0.00%
ACB Aurora Cannabis Inc. $3.84 N/A - +0.00%
CRSP CRISPR Therapeutics AG $60.14 N/A - +0.00%
A Agilent Technologies, Inc. $121.38 N/A 0.82% +0.00%
AHCO AdaptHealth Corp. $9.15 N/A - +0.00%
ABBV AbbVie Inc. $232.08 N/A 2.87% +0.00%

Community Sentiment

Sign in to vote

0% Bullish 0% Neutral 100% Bearish

0 votes

Discussion (0)

Sign in to join the discussion

Loading comments...

About 10x Genomics, Inc.

10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits. It also provides Visium platform, a spatial analysis platform that uses high density DNA arrays to encode the physical location of biological analytes within a sample. This platform includes HD WT panel gene expression, and HD 3' gene expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides. In addition, the company offers Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section without the need for conventional sequencing; and slides and reagents. Further, it provides various software products comprising Cell Ranger, a scRNA-seq processing pipeline in scientific literature; Loupe Browser, which enables intuitive single-cell, spatial, and multiomic data visualization; and Xenium Explorer that enables intuitive in situ data visualization, which allows researchers to explore subcellular gene expression, spatial organization, and tissue-scale patterns. The company serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

www.10xgenomics.com →

🐂 Bull Score

Our proprietary rating measures dividend reliability based on 6 fundamental factors including payout sustainability, financial strength, and cash flow coverage.

F 0/100

Very Risky

Bull Score

- No consecutive dividend growth 0/25
- Negative profit margin 0/15
Limited data — score may change as more metrics become available

Dividend Safety

Assessment based on payout ratio, debt levels, profit margins, and dividend growth track record.

35

Unsafe

Based on 4 fundamental factors

- Negative profit margin

Analysis Tools

Sign in for analysis tools

Share